The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action

Research output: Contribution to journal › Journal article › peer-review

Standard

The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. / Hare, Kristine J; Vilsbøll, Tina; Asmar, Meena; Deacon, Carolyn F; Knop, Filip K; Holst, Jens Juul.

In: Diabetes, Vol. 59, No. 7, 01.07.2010, p. 1765-70.

Research output: Contribution to journal › Journal article › peer-review

Harvard

Hare, KJ, Vilsbøll, T, Asmar, M, Deacon, CF, Knop, FK & Holst, JJ 2010, 'The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action', Diabetes, vol. 59, no. 7, pp. 1765-70. https://doi.org/10.2337/db09-1414

APA

Hare, K. J., Vilsbøll, T., Asmar, M., Deacon, C. F., Knop, F. K., & Holst, J. J. (2010). The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. Diabetes, 59(7), 1765-70. https://doi.org/10.2337/db09-1414

Vancouver

Hare KJ, Vilsbøll T, Asmar M, Deacon CF, Knop FK, Holst JJ. The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. Diabetes. 2010 Jul 1;59(7):1765-70. https://doi.org/10.2337/db09-1414

Author

Hare, Kristine J ; Vilsbøll, Tina ; Asmar, Meena ; Deacon, Carolyn F ; Knop, Filip K ; Holst, Jens Juul. / The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action. In: Diabetes. 2010 ; Vol. 59, No. 7. pp. 1765-70.

Bibtex

@article{87f0d1dbe1de46d09ec4ea166280e402,
title = "The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action",
abstract = "Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic beta- and alpha-cells. Previous studies have focused on the improvements in beta-cell function, while the inhibition of alpha-cell secretion has received less attention. The aim of this research was to quantify the glucagonostatic contribution to the glucose-lowering effect of GLP-1 infusions in patients with type 2 diabetes.",
keywords = "Adult, Analysis of Variance, Area Under Curve, Blood Glucose, Diabetes Mellitus, Type 2, Glucagon, Glucagon-Like Peptide 1, Glucose Clamp Technique, Humans, Insulin, Male, Middle Aged, Time Factors, Treatment Outcome",
author = "Hare, {Kristine J} and Tina Vilsb{\o}ll and Meena Asmar and Deacon, {Carolyn F} and Knop, {Filip K} and Holst, {Jens Juul}",
year = "2010",
month = jul,
day = "1",
doi = "10.2337/db09-1414",
language = "English",
volume = "59",
pages = "1765--70",
journal = "Diabetes",
issn = "0012-1797",
publisher = "American Diabetes Association",
number = "7",

}

RIS

TY - JOUR

T1 - The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucose-lowering action

AU - Hare, Kristine J

AU - Vilsbøll, Tina

AU - Asmar, Meena

AU - Deacon, Carolyn F

AU - Knop, Filip K

AU - Holst, Jens Juul

PY - 2010/7/1

Y1 - 2010/7/1

N2 - Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic beta- and alpha-cells. Previous studies have focused on the improvements in beta-cell function, while the inhibition of alpha-cell secretion has received less attention. The aim of this research was to quantify the glucagonostatic contribution to the glucose-lowering effect of GLP-1 infusions in patients with type 2 diabetes.

AB - Glucagon-like peptide 1 (GLP-1) exerts beneficial antidiabetic actions via effects on pancreatic beta- and alpha-cells. Previous studies have focused on the improvements in beta-cell function, while the inhibition of alpha-cell secretion has received less attention. The aim of this research was to quantify the glucagonostatic contribution to the glucose-lowering effect of GLP-1 infusions in patients with type 2 diabetes.

KW - Adult

KW - Analysis of Variance

KW - Area Under Curve

KW - Blood Glucose

KW - Diabetes Mellitus, Type 2

KW - Glucagon

KW - Glucagon-Like Peptide 1

KW - Glucose Clamp Technique

KW - Humans

KW - Insulin

KW - Male

KW - Middle Aged

KW - Time Factors

KW - Treatment Outcome

U2 - 10.2337/db09-1414

DO - 10.2337/db09-1414

M3 - Journal article

C2 - 20150286

VL - 59

SP - 1765

EP - 1770

JO - Diabetes

JF - Diabetes

SN - 0012-1797

IS - 7

ER -

ID: 33940158